Huda Zoghbi Sells 800 Shares of Regeneron Pharmaceuticals (NASDAQ:REGN) Stock

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Director Huda Zoghbi sold 800 shares of Regeneron Pharmaceuticals stock in a transaction on Monday, August 10th. The stock was sold at an average price of $800.00, for a total value of $640,000.00. Following the completion of the sale, the director directly owned 1,703 shares of the company’s stock, valued at $1,362,400. The trade was a 31.96% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Regeneron Pharmaceuticals Stock Up 1.0%

Regeneron Pharmaceuticals stock opened at $805.97 on Friday. Regeneron Pharmaceuticals, Inc. has a one year low of $541.00 and a one year high of $821.11. The stock has a fifty day moving average of $672.43 and a 200 day moving average of $713.71. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.78 and a current ratio of 3.34. The stock has a market cap of $82.98 billion, a PE ratio of 19.92, a price-to-earnings-growth ratio of 1.36 and a beta of 0.22.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $10.16 by $4.13. Regeneron Pharmaceuticals had a return on equity of 13.47% and a net margin of 27.86%.The business had revenue of $4.29 billion during the quarter, compared to the consensus estimate of $3.82 billion. During the same period in the previous year, the company posted $12.81 EPS. The business’s quarterly revenue was up 16.7% compared to the same quarter last year. As a group, sell-side analysts predict that Regeneron Pharmaceuticals, Inc. will post 44.25 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, August 31st. Investors of record on Tuesday, August 18th will be given a dividend of $0.94 per share. This represents a $3.76 annualized dividend and a yield of 0.5%. The ex-dividend date is Tuesday, August 18th. Regeneron Pharmaceuticals’s payout ratio is 9.29%.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on the stock. Citigroup lifted their price target on shares of Regeneron Pharmaceuticals from $700.00 to $740.00 and gave the stock a “neutral” rating in a research note on Monday, August 3rd. BMO Capital Markets decreased their target price on Regeneron Pharmaceuticals from $900.00 to $730.00 and set an “outperform” rating on the stock in a report on Monday, May 18th. Guggenheim lifted their target price on Regeneron Pharmaceuticals from $1,000.00 to $1,030.00 and gave the company a “buy” rating in a research report on Monday, August 3rd. TD Cowen boosted their price target on Regeneron Pharmaceuticals from $880.00 to $960.00 and gave the company a “buy” rating in a report on Thursday, April 23rd. Finally, Sanford C. Bernstein upgraded Regeneron Pharmaceuticals to a “hold” rating in a research report on Wednesday, July 29th. Sixteen research analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $793.74.

Institutional Trading of Regeneron Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of REGN. BlackRock Inc. purchased a new stake in Regeneron Pharmaceuticals in the 2nd quarter worth $5,682,636,000. Norges Bank purchased a new position in shares of Regeneron Pharmaceuticals in the fourth quarter valued at about $1,012,296,000. Price T Rowe Associates Inc. MD boosted its stake in shares of Regeneron Pharmaceuticals by 142.2% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,949,797 shares of the biopharmaceutical company’s stock worth $1,504,991,000 after acquiring an additional 1,144,887 shares during the period. Nuveen LLC boosted its stake in shares of Regeneron Pharmaceuticals by 71.1% in the fourth quarter. Nuveen LLC now owns 2,010,517 shares of the biopharmaceutical company’s stock worth $1,551,858,000 after acquiring an additional 835,240 shares during the period. Finally, Bank of New York Mellon Corp purchased a new stake in shares of Regeneron Pharmaceuticals during the second quarter worth about $472,950,000. 83.31% of the stock is currently owned by institutional investors.

Key Stories Impacting Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Regeneron agreed to collaborate with Parabilis Medicines on antibody-Helicon conjugates, providing Parabilis with $125 million in upfront consideration and an equity investment. Regeneron could also receive as much as $2.2 billion in milestone payments, plus tiered royalties, if the programs succeed. The deal expands Regeneron’s drug-development capabilities and adds potential long-term pipeline value. Parabilis Medicines Reports Second Quarter 2026 Financial Results and Provides Business Updates
• Positive Sentiment: Recent fundamentals remain supportive: Regeneron’s latest quarterly results exceeded analyst expectations, with earnings per share of $14.29 versus a $10.16 consensus and revenue of $4.29 billion versus estimates of $3.82 billion. Revenue increased 16.7% year over year, reinforcing investor confidence in the business and its ability to fund pipeline development.
• Neutral Sentiment: Directors Huda Y. Zoghbi and Kathryn Guarini sold $640,000 and $320,000 of stock, respectively, at approximately $800 per share. Both transactions were executed under pre-arranged Rule 10b5-1 plans, which reduces their usefulness as indicators of current management sentiment. Director Sale Filing
• Negative Sentiment: Multiple law firms publicized a securities class action tied to allegations that Regeneron misled investors about the prospects of its Phase 3 fianlimab-Libtayo trial for advanced melanoma. The trial’s failed primary endpoint reportedly erased about $11 billion in market value and may increase concerns about litigation expenses, disclosure practices and the oncology pipeline. Investors seeking lead-plaintiff status face a September 14, 2026 deadline. Regeneron Class Action Lawsuit Notice

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.